Credent Connect N Care Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Credent Connect N Care Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹189
Per ShareLot Size
600 Shares
Minimum Investment
₹1,13,400
Issue Size
₹93.9 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.12%
QIB Quota
49.87%
NII Quota
15.01%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Credent Connect N Care Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
87.52%
Promoter Holding (Post-Issue)
63.67%
Issue Type
Book Building - SME
ISIN
INE1KPX01025
About the Company
Our company is a healthcare services provider engaged in delivering integrated logistics, workforce solutions, and technology-enabled support to healthcare institutions across India. We provide comprehensive operational and logistics services to diagnostic laboratories, In Vitro Diagnostics (IVD) companies, pharmaceutical companies, clinics, and other healthcare enterprises through end-to-end solutions.
Company History
Our Company was originally incorporated as a Private Limited Company under the name of "Credent Cold Chain Logistics Private Limited" on June 25, 2015 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Delhi bearing CIN: U63000DL2015PTC281994. Further, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 12, 2024, the name of our Company was changed from "Credent Cold Chain Logistics Private Limited" to "Credent Connect N Care Private Limited" and a fresh certificate of incorporation consequent upon Change of Name was issued by the Registrar of Companies, CPC vide certificate dated May 10, 2024 bearing CIN: U63000DL2015PTC281994. Further, pursuant to a special resolution passed by the shareholder at extra Ordinary General Meeting held on September 15, 2025, company has converted from Private Limited to public limited and name of the company was changed from "Credent Connect N Care Private Limited" to "Credent Connect N Care Limited" and a fresh certificate of incorporation consequent upon conversion into public limited was issued by the Registrar of Companies, CPC vide certificate dated October 28, 2025 bearing CIN: U63000DL2015PLC281994.
Growth Strategy
- Continue to invest in technological capabilities.
- Deepen Client Engagement and Expand Services.
- Attract, develop and retain skilled employees.
- Enhancing Operating Effectiveness and Efficiency.
Financial Performance
Revenue, profit after tax and total assets for the last reported financial year.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of upto 49,68,000 equity shares of face value of Rs. 10 each (the "Equity Shares") of Credent Connect N Care Limited (formerly known as Credent Cold Chain Logistics Private Limited) ("the Company" or "Credent" or "the Issuer") at an issue price of Rs. 189 per equity share (including share premium of Rs. 179 per equity share) for cash, aggregating up to Rs. 93.90 Crores ("Public Issue") out of which 2,52,000 equity shares of face value of Rs. 10 each, at an issue price of Rs. 189 per equity share for cash, aggregating Rs. 4.76 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 47,16,000 equity shares of face value of Rs. 10 each, at an issue price of Rs. 189 per equity share for cash, aggregating upto Rs. 89.13 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.44% and 25.10% respectively of the post-issue paid-up equity share capital of the company. Price Band: Rs. 189 per equity share of face value Rs. 10 each. The floor price (Rs.189) is 18.90 times of the face value of the equity shares. Bids can be made for a minimum of 1200 equity shares and in multiples of 600 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Comprehensive Healthcare Ecosystem and Logistics Platform.
- Well established relationships with clients .
- Leveraging the experience of our Promoters and Directors .
- Widespread reach in domestic markets.
- The company derives a significant portion of its revenue from operations from the company's top 10 customers with which the company does not has any firm commitments. The loss of any one or more of its major customers would have a material adverse effect on the company's business, cash flows, results of operations and financial condition.
- The company's business is dependent on diagnostic and healthcare companies, and any reduction in their testing volumes, outsourcing requirements, or adverse sector developments could materially and adversely affect its business, financial condition, and results of operations.
- The company is exposed to risks relating to loss, damage, contamination or delay in transportation of diagnostic samples, which could result in client claims, financial liabilities and reputational harm.
- The company's business depends on service-level contracts with clients that are subject to renewal, renegotiation and termination, and its inability to maintain or renew such contracts on favourable terms could materially and adversely affect the company's business.
- The company's business is working capital intensive and trade receivables constitute a significant portion of its current assets. Any delay or failures in realisation of trade receivables could adversely affect its cash flows, liquidity and financial condition.